Lv3
226 积分 2021-10-24 加入
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics
14小时前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
8天前
已完结
First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance
1个月前
已完结
The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers
1个月前
已完结
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer
2个月前
已完结
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
2个月前
已完结
RET, ROS1 and ALK fusions in lung cancer
2个月前
已完结
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study
2个月前
已完结
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
2个月前
已完结
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
2个月前
已完结
皖公网安备34019202002308
